Top Midday Gainers

MT Newswires Live

3 hours ago

WeRide (WRD) reported on Monday a narrower net loss in Q4 as revenue jumped from a year ago.

Shares advanced 6.6% as intraday trading volume rose to over 13.7 million from a daily average of roughly 3.97 million.

Insmed (INSM) said a phase 3b study of Arikayce, as part of a multidrug regimen to treat patients with Mycobacterium avium complex lung infection, who have not started antibiotics, has met its primary and secondary endpoints.

Shares rose 4%, with intraday trading volume of more than 2.01 million against a daily average of about 2.38 million.

Wolfe Research upgraded Celldex Therapeutics (CLDX) to outperform from peer perform.

Shares rose 3.5% as intraday trading volume increased to over 902,000 from a daily average of about 847,000.

Price: 31.94, Change: +1.04, Percent Change: +3.37

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2621836200"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2621836200\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2621836200?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-24 01:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621836200","market":"fut","top_or_hot":-1,"title":"Top Midday Gainers","media":"MT Newswires Live","content":"<html><body><p> WeRide (WRD) reported on Monday a narrower net loss in Q4 as revenue jumped from a year ago.</p><p>Shares advanced 6.6% as intraday trading volume rose to over 13.7 million from a daily average of roughly 3.97 million.</p><p><a href=\"https://laohu8.com/S/INSM\">Insmed</a> (INSM) said a phase 3b study of Arikayce, as part of a multidrug regimen to treat patients with Mycobacterium avium complex lung infection, who have not started antibiotics, has met its primary and secondary endpoints.</p><p>Shares rose 4%, with intraday trading volume of more than 2.01 million against a daily average of about 2.38 million.</p><p>Wolfe Research upgraded Celldex <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (CLDX) to outperform from peer perform.</p><p>Shares rose 3.5% as intraday trading volume increased to over 902,000 from a daily average of about 847,000.</p><p>Price: 31.94, Change: +1.04, Percent Change: +3.37</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Top Midday Gainers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTop Midday Gainers\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-24 01:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> WeRide (WRD) reported on Monday a narrower net loss in Q4 as revenue jumped from a year ago.</p><p>Shares advanced 6.6% as intraday trading volume rose to over 13.7 million from a daily average of roughly 3.97 million.</p><p><a href=\"https://laohu8.com/S/INSM\">Insmed</a> (INSM) said a phase 3b study of Arikayce, as part of a multidrug regimen to treat patients with Mycobacterium avium complex lung infection, who have not started antibiotics, has met its primary and secondary endpoints.</p><p>Shares rose 4%, with intraday trading volume of more than 2.01 million against a daily average of about 2.38 million.</p><p>Wolfe Research upgraded Celldex <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (CLDX) to outperform from peer perform.</p><p>Shares rose 3.5% as intraday trading volume increased to over 902,000 from a daily average of about 847,000.</p><p>Price: 31.94, Change: +1.04, Percent Change: +3.37</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0053671581.USD","symbol_name":"摩根大通美国小盘成长股 A(dist)","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2621836200","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621836200","pubTimestamp":1774286997,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"WeRide  reported on Monday a narrower net loss in Q4 as revenue jumped from a year ago.Shares advanced 6.6% as intraday trading volume rose to over 13.7 million from a daily average of roughly 3.97 million.Insmed  said a phase 3b study of Arikayce, as part of a multidrug regimen to treat patients with Mycobacterium avium complex lung infection, who have not started antibiotics, has met its primary and secondary endpoints.Shares rose 4%, with intraday trading volume of more than 2.01 million against a daily average of about 2.38 million.Wolfe Research upgraded Celldex Therapeutics  to outperform from peer perform.Shares rose 3.5% as intraday trading volume increased to over 902,000 from a daily average of about 847,000.Price: 31.94, Change: +1.04, Percent Change: +3.37","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","BK4609":"英伟达持仓股","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4124":"机动车零配件与设备","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","CLDX":"塞德斯医疗","BK4139":"生物科技","WRD":"文远知行","00800":"文远知行-W","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","INSM":"Insmed"},"translate_title":"午盘涨幅最大的股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INSM":1.94,"CLDX":1.93,"WRD":1.94,"00800":1.94},"content_text":"WeRide (WRD) reported on Monday a narrower net loss in Q4 as revenue jumped from a year ago.Shares advanced 6.6% as intraday trading volume rose to over 13.7 million from a daily average of roughly 3.97 million.Insmed (INSM) said a phase 3b study of Arikayce, as part of a multidrug regimen to treat patients with Mycobacterium avium complex lung infection, who have not started antibiotics, has met its primary and secondary endpoints.Shares rose 4%, with intraday trading volume of more than 2.01 million against a daily average of about 2.38 million.Wolfe Research upgraded Celldex Therapeutics (CLDX) to outperform from peer perform.Shares rose 3.5% as intraday trading volume increased to over 902,000 from a daily average of about 847,000.Price: 31.94, Change: +1.04, Percent Change: +3.37","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}